IGT Applauds FDA’s Draft Framework to Speed Individualized Therapies, Urges Continued Alignment of Regulation with Breakthrough Treatments for Unmet Needs

The U.S. Food and Drug Administration (FDA) this week released a draft Plausible Mechanism Framework for recognizing the value of accelerating development for individualized therapies for rare and ultra-rare diseases. The draft guidance tackles a long‑standing barrier that has delayed access to potentially life‑saving treatments for people with rare conditions and proposes new ways to spur rare‑disease innovation through clear scientific criteria, closer regulatory collaboration, real‑world patient evidence, and sustained investment to keep America healthier and competitive in developing the next generation of cures.IGT Chairman Congressman Erik Paulsen issued the following statement:  

“This is a critical step toward aligning regulatory approaches with the realities of transformative treatments like gene therapy. FDA’s understanding that traditional randomized controlled trials are often infeasible for therapies targeting exceedingly small populations is critically important to the rare patient populations. Involving diverse patient voices, including Foundation for Angelman Syndrome Therapeutics’ Allyson Berent, in a pre‑launch roundtable is a positive step to reflect real‑world rare disease experience and the urgency for higher standards of care. For too long, regulations designed for large population trials have slowed progress for diseases where challenges are many and medical need too often goes unmet. These communities have waited years for breakthroughs that could change the trajectory of devastating disease, and this draft guidance represents a meaningful shift towards the possible implementation of a new framework that allows for further regulatory flexibility while also honoring scientific innovation.  

“We urge the FDA to continue refining this approach to ensure that regulatory frameworks keep pace with medicine and stand ready to support efforts that can make innovations like gene therapy a reality for all patients and families who may benefit from them.”